Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 4:31 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 1,256 matching trials from the live ClinicalTrials.gov search.
Conditions
Lymphoma
Interventions
filgrastim, gemcitabine hydrochloride, vinorelbine tartrate
Biological · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
108
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 93 more
Conditions
Lymphoma, B-Cell
Interventions
obinutuzumab, cyclophosphamide, doxorubicin, prednisone, vincristine
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
38
States / cities
Birmingham, Alabama • Encinitas, California • Aurora, Colorado + 34 more
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Melatonin Studies of Totally Blind Children

NCT00795236
Conditions
Sleep Disorder, Blindness
Interventions
Melatonin
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
5 Years to 20 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Lymphoma, Non-Hodgkin, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Lymphoma, Small-Cell, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone
Interventions
Rituximab, Bendamustine, Vincristine sulfate liposome injection
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Providence, Rhode Island
Conditions
Lymphoma
Interventions
Multiple drug microinjection: rituximab, vincristine, doxorubicin, bendamustine, prednisolone or a combination of them
Drug
Lead sponsor
Presage Biosciences
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Lymphoma
Interventions
filgrastim, recombinant interferon alfa, Etoposide, cyclophosphamide, doxorubicin hydrochloride, lamivudine, prednisone, vincristine sulfate, zidovudine
Biological · Drug
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years to 120 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
3
States / cities
Los Angeles, California • Miami, Florida • St Louis, Missouri
Conditions
B-cell Childhood Acute Lymphoblastic Leukemia, L1 Childhood Acute Lymphoblastic Leukemia, L2 Childhood Acute Lymphoblastic Leukemia, Intermediate Risk Recurrent Childhood Acute Lymphoblastic Leukemia
Interventions
vincristine sulfate, prednisone, doxorubicin hydrochloride, pegaspargase, cytarabine, methotrexate, dexamethasone, etoposide, cyclophosphamide, leucovorin calcium, filgrastim, asparaginase, mercaptopurine
Drug · Biological
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 29 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
159
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 126 more
Conditions
Follicular Lymphoma
Interventions
Combination of treatment modalities
Other
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Newborn Hypoxic Ischemic Encephalopathy
Interventions
Melatonin, placebo
Drug
Lead sponsor
St. Louis University
Other
Eligibility
1 Hour to 8 Hours
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Healthy Adult
Interventions
5 Methoxy N,N Dimethyltryptamine, GH001 Aerosol Delivery System
Drug · Device
Lead sponsor
GH Research Ireland Limited
Industry
Eligibility
21 Years to 64 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Miami, Florida
Completed Phase 1Phase 2 Interventional Results available

TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas

NCT01851369
Conditions
Lymphomas, Solid Tumors, NSCLC, Metastatic Colon Carcinoma, Granulosa Cell Ovarian Cancer
Interventions
TRC102, CT scan, Lomotil, Prochlorperazine, Metoclopramide, 5-HT3 antagonist, Aprepitant, Biopsy
Drug · Diagnostic Test · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Lymphoma
Interventions
filgrastim, CHOP regimen, carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, prednisone, vincristine sulfate, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
1
States / cities
New York, New York
Conditions
Diffuse Large B Cell Lymphoma, Post Transplant Lymphoproliferative Disorder, Primary Mediastinal (Thymic) Large B-cell Lymphoma
Interventions
DA-EPOCH-R for DLBCL, PTLD, AND PMBCL, Methotrexate, Etoposide, Doxorubicin, Vincristine, Rituximab, Cyclophosphamide, Prednisone, G-CSF
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 30 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Houston, Texas
Active, not recruiting Phase 2 Interventional

Evolutionary Therapy for Rhabdomyosarcoma

NCT04388839
Conditions
Rhabdomyosarcoma
Interventions
Vincristine, Cyclophosphamide, Vinorelbine, Actinomycin D, Cyclophosphamide Pill
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
18
States / cities
Birmingham, Alabama • Aurora, Colorado • Hartford, Connecticut + 15 more
Conditions
Lymphoma, Follicular
Interventions
Golcadomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Bendamustine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 15 more
Conditions
Brain and Central Nervous System Tumors, Neurofibromatosis Type 1
Interventions
carboplatin, vinblastine sulfate
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
19
States / cities
Birmingham, Alabama • Orange, California • Washington D.C., District of Columbia + 16 more
Conditions
Aging
Interventions
Psilocybin
Drug
Lead sponsor
University of California, Berkeley
Other
Eligibility
60 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Berkeley, California
Conditions
Lymphoma
Interventions
Ibrutinib, Placebo, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (or equivalent)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
838 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
44
States / cities
Tucson, Arizona • Greenbrae, California • La Jolla, California + 41 more
Conditions
AIDS-Related Burkitt Lymphoma, AIDS-Related Diffuse Large B-cell Lymphoma, AIDS-Related Plasmablastic Lymphoma, AIDS-Related Primary Effusion Lymphoma, HIV Infection, AIDS Related Non-Hodgkin Lymphoma
Interventions
Prednisone, Rituximab, Etoposide, Doxorubicin Hydrochloride, Vincristine Sulfate, Cyclophosphamide, Filgrastim, Lentivirus Vector rHIV7-shI-TAR-CCR5RZ-transduced Hematopoietic Stem/Progenitor Cells
Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Terminated Not applicable Interventional Accepts healthy volunteers

Melatonin Treatment for Night-Eating Syndrome

NCT02500017
Conditions
Night-eating Syndrome
Interventions
Melatonin, Placebo
Dietary Supplement · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia
Interventions
Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Collection, Computed Tomography, Cyclophosphamide, Doxorubicin, Etoposide, Filgrastim, Pegfilgrastim, Positron Emission Tomography, Prednisone, Rituximab, Vincristine
Drug · Procedure · Biological
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Lymphoma
Interventions
filgrastim, cytarabine, doxorubicin hydrochloride, leucovorin calcium, mercaptopurine, methotrexate, prednisone, vincristine sulfate, low-LET cobalt-60 gamma ray therapy, low-LET electron therapy, low-LET photon therapy
Biological · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2006
U.S. locations
8
States / cities
Wichita, Kansas • New Orleans, Louisiana • Asheville, North Carolina + 5 more
Conditions
Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma
Interventions
Bone Marrow Biopsy, Cyclophosphamide, Doxorubicin, Prednisone, Retifanlimab, Rituximab and Hyaluronidase Human, Tafasitamab, Vincristine, Bone Marrow Aspiration, Multigated Acquisition Scan, Fludeoxyglucose F-18, Positron Emission Tomography, Computed Tomography, Biospecimen Collection, Polatuzumab Vedotin
Procedure · Drug · Biological + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Treatment Resistant Depression
Interventions
Psilocybin
Drug
Lead sponsor
COMPASS Pathways
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
40
States / cities
Tuscon, Arizona • Culver City, California • Garden Grove, California + 30 more